智通财经APP讯，科笛-B(02487)发布公告，集团CU-10201(外用4%米诺环素泡沫剂)治疗中度至重度面部寻常痤疮的早期疗效的一项中国III期临床试验的事后分析被选为在第二十届中国医师协会皮肤科医师年会暨全国美容皮肤科学大会(第二十届CDA年会)上口头发言。
CU-10201是全球首个且唯一一个获批用于寻常痤疮治疗的外用米诺环素，也是首个获得中国国家药品监督管理局优先审评审批资格批准上市的外用米诺环素。 CU-10201针对中国中度至重度寻常痤疮患者的12周疗效与安全性已通过 III 期临床试验证实。本事后分析旨在评估CU-10201在中国中度至重度面部寻常痤疮患者于治疗第一周和第二周的早期疗效。
疗效分析显示，CU-10201在治疗中国中度至重度面部寻常痤疮患者中，表现出快速起效的显著特点。于治疗第一周即可观察到炎性皮损的显著改善，而第二周时疗效进一步增强。这些早期疗效资料表明，CU-10201可为寻常痤疮患者提供快速缓解症状的治疗选择，具有重要的临床意义。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.